These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23394553)

  • 1. Statin intolerance: why and what to do - with a focus on diabetic people.
    Matteucci E; Giampietro O
    Curr Med Chem; 2013; 20(11):1397-408. PubMed ID: 23394553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Statins and the risk of diabetes].
    Simonyi G
    Orv Hetil; 2013 Oct; 154(43):1691-5. PubMed ID: 24140507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of heat shock proteins by statins.
    Forouzanfar F; Butler AE; Banach M; Barreto GE; Sahbekar A
    Pharmacol Res; 2018 Aug; 134():134-144. PubMed ID: 29935271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Situational Analysis of Low-density Lipoprotein Cholesterol Control and the Use of Statin Therapy in Diabetes Patients Treated in Community Hospitals in Nanjing, China.
    Ouyang XJ; Zhang YQ; Chen JH; Li T; Lu TT; Bian RW
    Chin Med J (Engl); 2018 Feb; 131(3):295-300. PubMed ID: 29363644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients.
    Sukhija R; Prayaga S; Marashdeh M; Bursac Z; Kakar P; Bansal D; Sachdeva R; Kesan SH; Mehta JL
    J Investig Med; 2009 Mar; 57(3):495-9. PubMed ID: 19188844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond statin therapy: a review of the management of residual risk in diabetes mellitus.
    Judge EP; Phelan D; O'Shea D
    J R Soc Med; 2010 Sep; 103(9):357-62. PubMed ID: 20807991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin Intolerance.
    Brown AS; Watson KE
    Rev Cardiovasc Med; 2018; 19(S1):S9-S19. PubMed ID: 30207553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reviewing statin therapy in diabetes--towards the best practise.
    Matikainen N; Kahri J; Taskinen MR
    Prim Care Diabetes; 2010 Apr; 4(1):9-15. PubMed ID: 20171948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
    Degli Esposti L; Sangiorgi D; Arca M; Vigna GB; Budal S; Degli Esposti E
    Monaldi Arch Chest Dis; 2011 Dec; 76(4):160-7. PubMed ID: 22567731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting.
    Simpson RJ; Tunceli K; Ramey DR; Neff DR; Kern DM; Hsieh HM; Wertz DA; Stephenson JJ; Marrett E; Tomassini JE; Jacobson TA
    J Clin Lipidol; 2013; 7(5):399-407. PubMed ID: 24079280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CONTROVERSIAL ISSUES IN THE TREATMENT OF DYSLIPIDEMIAS IN PATIENTS WITH DIABETES MELLITUS.
    Parhofer KG
    Rev Invest Clin; 2018; 70(5):237-243. PubMed ID: 30307445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.
    Ginsberg HN
    J Clin Endocrinol Metab; 2006 Feb; 91(2):383-92. PubMed ID: 16291700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lipids-Diagnosis and therapy in diabetes mellitus (Update 2019)].
    Wascher TC; Paulweber B; Toplak H; Saely CH; Drexel H; Föger B; Hoppichler F; Stulnig T; Stingl H; Clodi M;
    Wien Klin Wochenschr; 2019 May; 131(Suppl 1):136-138. PubMed ID: 30980157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug therapy of diabetic dyslipidemia: do the statins suffice?
    Mooradian AD
    Am J Ther; 2015; 22(1):87-8. PubMed ID: 23728161
    [No Abstract]   [Full Text] [Related]  

  • 19. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.